9 peptides in this category. Click any to open its calculator.
This group targets mitochondrial function, NAD+ metabolism and cellular senescence. It contains one FDA-approved medicine — elamipretide, for Barth syndrome — and a set of compounds whose human evidence stops well short of that. Dose disagreements here are unusually wide: community sources for the same bioregulator differ by up to 1000×, which is the signature of a quantity nobody has measured. Mitochondrial uncouplers deserve particular care, as that class has a documented history of human deaths. Every titration table below records where its numbers come from. The split inside this group is worth keeping in view. On one side sit compounds with a named mechanism and a regulator behind them, where the dose in the table is the dose in the label. On the other sit peptides whose entire published record is a handful of small studies from a single research lineage, sometimes uncontrolled, sometimes measuring a biomarker rather than an outcome. The calculators treat both the same way, because arithmetic does not care; the review notes do not, and they say which is which before you reach for a syringe.
